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The rate of endochondral bone growth determines final height in humans and is tightly controlled.
Glycogen synthase kinase-3 (GSK-3) is a negative regulator of several signaling pathways that
govern bone growth, such as insulin/IGF and Wnt/␤-catenin. The two GSK-3 proteins, GSK-3␣ and
GSK-3␤, display both overlapping and distinct roles in different tissues. Here we show that pharmacological inhibition of GSK-3 signaling in a mouse tibia organ culture system results in enhanced
bone growth, accompanied by increased proliferation of growth plate chondrocytes and faster
turnover of hypertrophic cartilage to bone. GSK-3 inhibition rescues some, but not all, effects of
phosphatidylinositide 3-kinase inhibition in this system, in agreement with the antagonistic role
of these two kinases in response to signals such as IGF. However, cartilage-specific deletion of the
Gsk3b gene in mice has minimal effects on skeletal growth or development. Molecular analyses
demonstrated that compensatory up-regulation of GSK-3␣ protein levels in cartilage is the likely
cause for this lack of effect. To our knowledge, this is the first tissue in which such a compensatory
mechanism is described. Thus, our study provides important new insights into both skeletal development and the biology of GSK-3 proteins. (Endocrinology 152: 1755–1766, 2011)

M

ost bones develop through endochondral ossification, in which a cartilage scaffold is first produced
by chondrocytes and then converted to calcified bone tissue by bone-forming cells, osteoblasts. Chondrocytes of
the growth plate are responsible for longitudinal growth
of endochondral bones (reviewed in Refs. 1 and 2). The
growth plate is divided into three distinct zones that can be
identified by histological features, rate of cell cycle progression, or marker gene expression. The resting zone is
farthest from the midbone (diaphysis) and consists of
small chondrocytes with little cytoplasm and relatively
low rates of proliferation. Some of these cells mature into
proliferative zone chondrocytes that undergo rapid proliferation, resulting in flattened columnar cells surrounded
by cartilage matrix. The proliferating chondrocytes then
withdraw from the cell cycle and differentiate further into

prehypertrophic and ultimately hypertrophic chondrocytes residing at the interface between growth plate cartilage and ossified bone. These hypertrophic cells represent the terminal differentiation stage and secrete a large
amount of matrix and regulatory proteins. Finally, the
hypertrophic cells die by apoptosis and leave behind a
cartilage matrix that is invaded by blood vessels accompanied by osteoblast (bone-forming) and osteoclast
(bone-resorbing) precursors, ultimately resulting in the
replacement of cartilage by bone tissue (reviewed in
Refs. 3– 8).
The rate at which the chondrocytes progress through
the zones of the growth plate determines the longitudinal
growth of bone. This rate is consequently extremely important for normal skeletal development and final height
in humans and is therefore tightly regulated both intrin-
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role of GSK-3 signaling in chondrocytes using an organ
culture system and cartilage-specific inactivation of the
Gsk3b gene.

Materials and Methods
Materials
The following antibodies were used in this study: actin A5441
(Sigma Chemical Co., St. Louis, MO); cyclin D1 RM-9104-S1
(Neomarkers, Fremont, CA); goat antirabbit horseradish peroxidase (hrp) sc-2004, goat antimouse hrp sc-2005, p57/Kipp2
sc-8298 (Santa Cruz Biotechnology, Santa Cruz, CA); GSK-3␤
no. 9315, pGSK-3␤ no. 9336, GSK-3␣ no. 9338, pGSK-3␣ and
-␤ no. 9331, and ␤-catenin no. 9562 (Cell Signaling Technology,
Danvers, MA). General chemicals and supplies were purchased
from Sigma and VWR (Radnor, PA); organ culture reagents were
from Invitrogen (Carlsbad, CA).

Mouse breeding and genotyping
Mice homozygous for floxed Gsk3b alleles (Gsk3bfl/fl) have
been described previously (16, 38). Gsk3bfl/fl mice were crossed
with mice expressing cre recombinase under control of the cartilage-specific mouse Col2a1 promoter, donated by Drs. R. StArnaud and G. Karsenty, that we previously used in our lab (39,
40). Mice heterozygous for the floxed Gsk3b allele and expressing Col2a1 cre were backcrossed with homozygous Gsk3b
floxed mice. The offspring from these crosses were analyzed.
Mice were exposed to a 12-h light, 12- h dark cycle and fed tap
water and regular chow ad libitum. All procedures involving
animals were approved by the University of Western Ontario
Animal Care and Use Committee. PCR genotyping was performed from ear notch DNA using primers 5⬘-GGGGCAACCTTAATTTCATT-3⬘ (forward) and 5⬘-TCTGGGCTATAGCTATCTAGTAACG-3⬘ (reverse) for GSK-3␤ for 30 cycles of 96
C for 55 sec, 56.5 C for 45 sec, and 68 C for 2 min 45 sec to
amplify. The cre transgene was detected using the primers 5⬘CACACTGTGTAGTGCTTCGT-3⬘ (forward) and 5⬘-CCTCCAAACCATCCAAGAT-3⬘ (reverse) using 40 cycles of 95 C for
45 sec, 58 C for 30 sec, and 72 C for 1 min.

Organ culture
Tibias were isolated from embryonic d 15.5 (e15.5) mice and
cultured for 6 d in serum-free medium containing ␣-MEM,
ascorbic acid, ␤-glycerophosphate, BSA, glutamine, and penicillin-streptomycin as described, without exogenous growth factors (15, 41). After dissection, tibias were incubated in medium
overnight and then treated with dimethylsulfoxide (DMSO)
(control) or the GSK-3 inhibitor SB415286 (SB86; 10 M), PI3K
inhibitor LY 294002 (10 M LY), or a combination of the two
inhibitors. Please note that SB86 inhibits both GSK-3 proteins
(42). Media and inhibitor were changed every 48 h. Length of
tibias was measured before start of treatment and at the end of
6 d. Each independent experiment consisted of five to six tibias
per treatment; data represent averages from at least three independent experiments. These bones were then either stained with
alcian blue/alizarin red or prepared for paraffin embedding, sectioned, and analyzed by immunohistochemistry (IHC).
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sically and extrinsically by a complicated network of signaling pathways (reviewed in Refs. 2 and 9 –11).
Many of these signaling pathways have been linked to
the regulatory kinase glycogen synthase kinase-3 (GSK-3).
Two pathways with relevance to this study are insulin or
IGF/phosphatidylinositide 3-kinase (PI3K)/AKT/GSK-3
(12–16) and Wnt/GSK-3/␤-catenin (14, 17, 18). GSK-3 is
a serine/threonine kinase capable of phosphorylating a
large number of substrates including glycogen synthase,
from where its name originated, but its role in physiology
has expanded exponentially since its discovery. GSK-3 is
an unusual kinase in that it is constitutively active and
usually negatively regulates pathways (19 –21). Mammals
have two GSK-3 proteins, GSK-3␣ and GSK-3␤ (encoded
by different, highly homologous genes), with masses of 51
and 47 kDa, respectively. Regulation of GSK-␣ and -␤ can
occur through at least two mechanisms: 1) through direct
phosphorylation (Ser21 and Ser9 of GSK-3␣ and -␤, respectively), for example by the PI3K/AKT (12) signaling
pathway, or 2) through disruption of the protein complex
involved in canonical Wnt signaling (22). Potential cross
talk between these two pathways is highly debated as is the
relationship between the two GSK-3 proteins, GSK-3␣
and -␤. Many studies have demonstrated that phosphorylation of GSK-3 does not affect ␤-catenin levels, whereas
other studies have suggested it can (23–27). Likewise,
there is evidence for both overlapping and distinct roles of
GSK-3␣ and GSK-3␤ (16, 17, 28 –31). Tissue-specific
roles and relations could explain some of these seemingly
contradictory results (16, 32).
Several groups have examined how genetic manipulation of Gsk3b affects the skeleton (33, 34). The germline homozygous deletion of Gsk3b shows a variable
phenotype depending on the genetic background and
can result in embryonic lethality (33) or survival to postnatal d 0 (P0) with cleft palate, bifid sternum, and delayed ossification of the sternum, skull, ear bones, and
cranial base (34). Heterozygous deletion of Gsk3b also
causes a skeletal phenotype with increased ossification,
clavicle abnormalities and increased bone resorption (35).
It would appear that these opposing skeletal phenotypes
are Gsk3b dosage-dependent effects; however, all these
are phenotypes based on germline loss of Gsk3b. Consequently it is unclear whether these skeletal phenotypes are
cell or tissue autonomous. Interestingly, GSK-3␣ global
knockout (KO) mice have also been created; these are viable and fertile with similar body mass compared with
controls (36) but display abnormalities in glucose metabolism and brain structure (16, 36, 37) without any described skeletal abnormalities. The two global KO models
suggest that GSK-3␤ may play a more important role in
skeletal development than GSK-3␣. Here we address the

Endocrinology, May 2011, 152(5):1755–1766

Endocrinology, May 2011, 152(5):1755–1766

endo.endojournals.org

1757

Western blot analyses
Fresh calvaria, cartilage from the epiphyseal ends of long bones (humerus, femur, and
tibia), and organs were dissected from P0 mice
FIG. 1. Expression of GSK-3 proteins in the growth plate. Expression of GSK-3␣ and
in cold Puck’s solution A (39, 45). Samples
-␤ proteins in the growth plate of wild-type P0 tibia was analyzed by IHC. Although
GSK-3␤ expression was detected in chondrocytes of the articular surface (arrow)
were flash frozen in RIPA buffer and stored at
and in particular in prehypertrophic and hypertrophic chondrocytes, GSK-3␣ is
⫺20 C overnight and then homogenized, sonexpressed in all zones of the growth plate. Both proteins are also expressed in
icated, and centrifuged. Total protein content
the perichondrium (P), although GSK-3␤ was restricted to the cells closest to
was determined, and 25–35 g total protein
hypertrophic chondrocytes (H), and GSK-3␣ was again uniformly expressed
(depending on protein yield) was loaded per
throughout the cells of the perichondrium.
lane in precast NuPAGE Novex Midi Tris-acetate gels and separated using the XCell SureTibia staining
lock Mini-cell (Invitrogen) system. Gels were blotted using
Tibia staining was performed as described previously (39,
XCell II Blot Module (Invitrogen) as per the manufacturer’s
43). Organ culture tibias isolated from e15.5 embryos were deinstructions. Blots were blocked in 5% BSA Tris-buffered sahydrated in 95% ethanol for 24 h, followed by acetone for 24 h.
line/Tween 20 solution for 1 h and then probed with primary
Tibias were stained with 0.015% alcian blue, 0.05% alizarin red,
antibody overnight at 4 C. After washing (Tris-buffered saand 5% acetic acid in 70% ethanol. The stained tibias were
line/Tween 20), membranes were incubated with appropriate
stored in glycerol/ethanol (1:1). Images were taken with a Nikon
secondary antibody (hrp conjugated) for 1 h at room temperSMZ1500 dissecting microscope with a Photometrics (Tucson,
ature, and the resultant signal was detected using the ECL
AZ) Coolsnap camera using ImageMaster version 5.0 software.
detection system (Amersham, Piscataway, NJ). RepresentaAt least three independent experiments containing four to six
tive blots from at least three independent pairs of littermates
tibias per treatment (n) were used.
are shown. Quantitative densitometry analysis was conducted
using a ChemiImager 5500 system (Alpha Innotech, Miami,
Histology and IHC
FL), subtracting background and normalizing to ␤-actin loading control signal. Densitometry results were converted relaOrgan culture and isolated P0 tibias were fixed in 4% parative to control, allowing comparison between blots and comformaldehyde overnight and decalcified with 0.1 M EDTA/PBS at
pared statistically by t test analysis.
room temperature before paraffin embedding and sectioning at
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the Robarts Research Institute Molecular Pathology Core Facility (London, Ontario, Canada). Five-micrometer sections were dewaxed in
xylene followed by a graded series of ethanol
washes (100% twice, 95% once, and 70% once).
Sections were stained with either hematoxylin
and eosin or safranin O/fast green (39, 40, 43,
44). For IHC, sections were incubated in 3%
H2O2 for 15 min at room temperature, followed
by antigen retrieval by incubation in either 10
mM sodium citrate at 95 C for 30 min or 0.1%
Triton X-100 for 10 min, followed by blocking
with 5% goat serum in PBS. Sections were incubated with primary antibody overnight at 4 C
and washed (four times in PBS), and secondary
antibody was applied according to manufacturers’ recommendations. For detection, diaminobenzidine substrate was used and counterstained
with methyl blue. All images were taken with a
Leica DME microscope with a Qimaging MircroPublisher 5.0 RTV camera using QCapture
Pro version 5.1 software (Surrey, British Columbia, Canada).
Quantification of IHC was conducted depending on the target protein. For quantification
of proliferating cell nuclear antigen (PCNA)
IHC, the positively stained (brown) and total nuclei were counted to determine the fraction of
PCNA-positive cells in the growth plate. The
quantification of p57 protein in the growth plate
was conducted by measuring the length (proximal to distal) of the prehypertrophic zone where
darkly stained (brown) nuclei are present.
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Results

GSK-3 inhibition increases bone
growth and affects growth plate
morphology
To determine the role that GSK-3
FIG. 2. Inhibition of GSK-3 increases bone growth and changes growth plate organization.
plays in endochondral bone growth,
The e15.5 mouse tibias were cultured in organ culture for 6 d with a pharmacological
inhibitor of GSK-3 (10 M SB86) or DMSO [control (Cont)]. A, Representative picture of tibias
e15.5 tibia organ cultures were culstained with alizarin red (bone) and alcian blue (cartilage); B, quantification of growth
tured for 6 d with the pharmacological
(millimeters) of the tibia during the 6 d of treatment; C, Hematoxylin and eosin-stained
GSK-3 inhibitor SB86 (10 M) that inparaffin sections of organ culture tibias comparing morphology and growth plate zones, e.g.
resting and proliferating zones (R/P) and hypertrophic zone (H); D, length (millimeters) of the
hibits both GSK-3 proteins (42). Lonproximal tibia growth plate in control and SB86-treated tibias; E, resting and proliferating
gitudinal growth over this time was
zone length (millimeters) in control and GSK-3-inhibited organ culture; F, hypertrophic zone
compared with controls treated with
length (millimeters) in control and GSK-3-inhibited organ culture; G, quantification of the
DMSO. Tibia treated with SB86 grew
proportion of mineralized bone relative to the whole tibia length in control and GSK-3inhibited organ culture. All data were compared using t test analysis, and significant
31% more than controls over the 6 d of
differences are denoted by asterisks (n ⬎ 8; *, P ⬍ 0.05).
organ culture (Fig. 2, A and B). A similar trend, although not statistically sigStatistical analysis
nificant with a completed n of 3, was also observed using
All data were collected from at least three independent organ
another GSK-3 inhibitor, 10 M SB216763 (Supplemental
culture trial or pairs of littermates. Data are expressed as mean ⫾
Fig.
1A, published on The Endocrine Society’s Journals
SE, and P values ⬍ 0.05 were considered significant. For general
Online
web site at http://endo.endojournals.org). SB86
measurements and comparisons between two groups of data,
statistical significance was determined by unpaired t test comwas used exclusively for the remainder of the experiments.
paring control with treated (SB86) or control with cartilageInterestingly, this increase in bone growth did not affect
specific deletion of GSK-3␤ (KO) littermates using GraphPad
the overall length of the growth plate of the treated tibia
Prism version 3.00 for Windows. Western blot densitometry
(Fig. 2, C and D). However, inhibition of GSK-3 did affect
data were normalized to controls and compared by t test. Comthe organization and relative lengths of the zones within
parison of multiple treatments was done using one-way ANOVA
(normal distribution analyzed) and a Tukey posttest.
the growth plate (Fig. 2, E and F). The division between the
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GSK-3 expression in the growth
plate
To determine the expression patterns
of both GSK-3 proteins in the growth
plate in vivo, we performed IHC on wildtype P0 mouse tibia. GSK-3␤ was expressed at low levels in chondrocytes at
the articular surface and hardly detectable by IHC in resting and proliferating
chondrocytes but strongly expressed in
prehypertrophic and hypertrophic chondrocytes (Fig. 1). GSK-3␤ in the hypertrophic chondrocytes appears both cytoplasmic and nuclear with the highest
concentration being nuclear. In contrast, GSK-3␣ showed strong expression throughout the growth plate and
appeared to be more cytoplasmic than
GSK-3␤. Both proteins were also expressed in the perichondrium where
GSK-3␤ appeared confined to the layer
of cells closest to hypertrophic chondrocytes and GSK-3␣ was again more
uniformly expressed through the cells
of the perichondrium.
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GSK-3 inhibition rescues most
effects of PI3K inhibition in organ
culture
GSK-3 activity is regulated through
N-terminal phosphorylation by the insulin/PI3K/Akt pathway (12, 46) as
well the IGF/PI3K/Akt pathway that is
an important regulator of chondrocyte
physiology (15, 47). We previously
showed that PI3K inhibition decreased
bone growth and the length of the proliferating and hypertrophic zones (15).
Given that PI3K activates protein kinase B/Akt that in turn phosphorylates
and inhibits GSK-3, inhibition of PI3K
should activate GSK-3 and therefore have
opposite effects as inhibiting GSK-3. Furthermore,ifinactivationofGSK-3isone of
the main effectors of PI3K signaling
in endochondral bone growth, then
GSK-3 inhibition should rescue the effects of PI3K inhibition, at least in part.
To explore interactions between PI3K/
Akt and GSK-3, the effects of treatments with a PI3K inhibitor (10 M LY)
FIG. 3. Interaction of PI3K and GSK-3 signaling in organ culture. Tibia organ cultures (e15.5)
were treated with GSK-3 inhibitor (10 M SB86), PI3K inhibitor (10 M LY), a combination of
in combination with the GSK-3 inhibboth inhibitors (10 M SB6 plus 10 M LY), or DMSO [control (Cont)] for 6 d. A, IHC analyses
itor (10 M SB86) on tibia organ culof GSK-3 phosphorylation using phosphospecific antibodies specific for GSK-3␤ (top) or both
tures were examined (Fig. 3).
GSK-3␣ and ␤ (bottom); B, representative picture of tibias after 6 d of culture stained with
alizarin red (bone) and alcian blue (cartilage); C, quantification of longitudinal growth of tibias
To confirm that the inhibition of
(millimeters) over 6 d of culture; D, resting and proliferating zone length (micrometers) of
PI3K would indeed affect the phosbones treated with the various inhibitors; E, hypertrophic zone length (micrometers) of bones
phorylation of GSK-3 in our tibia organ
treated with the various inhibitors. All data were compared using one-way ANOVA with a
culture model, IHC analyses were conTukey posttest analysis; significant differences are denoted by asterisks (n ⫽ 3; *, P ⬍ 0.05).
ducted using antibodies specific to
phosphorylated GSK-3␤ (Fig. 3A, top)
resting and proliferating zones was much less distinct in
the SB86-treated bones, and therefore the zone measure- or to phosphorylated forms of both GSK-3 proteins (Fig.
ments combined both resting and proliferating zones for 3A, bottom). These data show that phosphorylation for
accuracy of measurements. The resting and proliferating GSK-3␤ was consistently decreased with LY treatment
zones of the treated tibia were 13% longer than the con- through the prehypertrophic/hypertrophic zones where
trols (Fig. 2E), whereas the length of hypertrophic zone GSK-3␤ is primarily expressed in the growth plate (Fig.
was significantly decreased by 57% (Fig. 2F). Because the 3A, top). The IHC detecting both phospho-GSK-3␣ and -␤
inhibition of GSK-3 caused increased tibia growth but demonstrated a decrease in the GSK-3 phosphorylation
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the total growth plate length was not
increased, we examined the mineralized portion of the tibia (Fig. 2G). The
mineralized portion of the tibia was
found to be significantly longer as a
ratio of total tibia length. These results together suggest that inhibition
of GSK-3 promotes long bone longitudinal growth by increasing bone
formation.
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Chondrocyte-specific ablation of
GSK-3␤ in vivo
To determine whether the ex vivo tibia
organ cultures results would translate
into an in vivo model and to address the
roles of individual GSK-3 proteins, we
generated mice with cartilage-specific
loss of GSK-3␤. Mice homozygote for the
floxed alleles of GSK-3␤ (Gsk3bfl/fl) (16,
38) were crossed with mice heterozygote
for the floxed allele and expressing
cre recombinase gene under control of
the mouse collagen II (Col2a1) proFIG. 4. Cartilage-specific deletion of GSK-3␤. Cartilage-specific GSK-3␤ KO mice carrying
moter (Gsk3bfl/wt cre⫹) (39, 48). This
two alleles of the floxed Gsk3b gene and expressing cre recombinase under the control of the
breeding scheme produced cartilage-specollagen II (Col2a1) promoter (KO) were created and compared with the control littermates
(Cont). Panel A, Western blot analyses using GSK-3␤ antibodies conducted on growth plate
cific GSK-3␤ deletion in (Gsk3bfl/fl
(GP) protein extracts from newborn littermate mice of Gsk3bfl/fl cre⫹ (KO) and control
fl/fl
cre⫹) referred to as knockout mice
(Gsk3b cre⫺, or Gsk3bfl/wt cre⫺) (Cont) genotype; panel B, densitometric quantification of
(KO), heterozygous mice (Gsk3bfl/wt
GSK-3␤ protein in P0 growth plate extracts; panel C, IHC using GSK-3␤ antibodies on
paraffin sections of P0 tibia, with black box in top image indicating the location of the lower
cre⫹), as well as control (Cont) litterhigher-magnification images; panel D, Western blot analyses of GSK-3␤ protein in calvarial
mates (Gsk3bfl/fl cre⫺ or Gsk3bfl/wt
tissue (Calv); panel E, Western blot analyses of GSK-3␤ protein in heart, brain, and kidney
cre⫺). Efficiency of GSK-3␤ deletion was
protein samples of control (C) and KO mice; panel F, tibia length (millimeters) measurements
from P0 control and KO mice; panel G, paraffin sections of P0 tibias from control and KO
determined through Western blot analymice stained with safranin O. All Western blot analyses used ␤-actin as a loading control.
sis and immunohistochemistry (Fig. 4).
Quantification used t test analyses where significance was denoted with an asterisk (n ⬎ 3;
Long bone growth plate extracts from P0
*, P ⬍ 0.05).
mice demonstrated an 80% reduction in
GSK-3␤ protein in KO cartilage (Fig. 4 A,
through the resting and proliferating zones but a less significant change in the prehypertrophic zone (Fig. 3A, bot- B). Immunohistochemistry (IHC) of P0 tibia paraffin section
tom). This suggests that GSK-3␣, which is more widely demonstrated strong expression of GSK-3␤ in the prehyperexpressed in the growth plate, is the predominate GSK-3 trophic and hypertrophic zones of control mice with virtually
form targeted by inhibition of the PI3K pathway through a complete loss of signal in KO littermates (Fig. 4 C). GSK-3␤
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the resting and proliferating zones,
whereas GSK-3␤ is the main target in
the prehypertrophic zone.
Consistent with our earlier studies,
SB86 (Fig. 2) increased and LY (15) decreased tibia growth in culture (Fig. 3, B
and C). The effect of the PI3K inhibitor
was partially recovered by the combination with the GSK-3 inhibitor (LY
plus SB86) (Fig. 3, B and C). None of
the treatments had significant effects on
the total length of the growth plates
(Supplemental Fig. 1B). Similar to the
bone growth, the combination of the
inhibitors was able to partially recover
the effect of PI3K inhibition on the
length of the resting/proliferative zone
(Fig. 3D), whereas both inhibitors individually and in combination reduced
the length of the hypertrophic zone
(Fig. 3E).
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P0 (Fig. 4F) and at P21 (Supplemental
Fig. 2C) were not significantly different
from control mice. The growth plate
zones were also not visually affected
upon cartilage-specific GSK-3␤ deletion
(Fig. 4G, Supplemental Fig. 2, D–F).

protein levels were explored in many tissues to evaluate the
specificity of the deletion (Fig. 4, D and E). Calvaria tissue
samples showed that GSK-3␤ expression was not affected in
bone tissue (Fig. 4D). No loss of GSK-3␤ protein was observed in any other tissues of KO mice (Fig. 4E).
The cartilage-specific GSK-3␤ KO mice did not display an
observable skeletal phenotype (Supplemental Fig. 2, A and
B). The size and weight of KO mice were similar to those of
control sex-matched littermates throughout their life, from
birth to 1 yr (data not shown). The length of the tibias at birth

Prehypertrophic cell cycle exit
increased upon GSK-3 inhibition
Hypertrophic chondrocyte differentiation is initiated by cell cycle exit, giving rise to prehypertrophic chondrocytes (49, 50). The cyclin-dependent
kinase inhibitor p57 is both a marker of prehypertrophic
chondrocytes and promotes cell cycle exit in the growth
plate (49 –54). In tibia organ culture, inhibition of GSK-3
or dual treatments of GSK-3 and PI3K inhibitors greatly
increased the zone of p57 protein expression in the prehypertrophic zone (Fig. 6A, black arrows in insets),
whereas the addition of the PI3K inhibitor did reduce this
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FIG. 5. GSK-3 inhibition increases proliferation in organ culture, whereas GSK-3␤ deletion in
cartilage has no effect on proliferation in vivo. PCNA was used to stain proliferating cells in
both tibia organ culture experiments and cartilage-specific GSK-3␤ KO mice. A, IHC analyses
of PCNA on paraffin section of tibia organ cultures treated with GSK-3 inhibitor (10 M
SB86), PI3K inhibitor (10 M LY), a combination of both inhibitors (10 M SB86 plus 10 M
LY), or DMSO [control (Cont)]. B, Quantification of the PCNA staining from A as percentage
of stained cells to total cells. Results were statistically compared using a one-way ANOVA with
Tukey posttest analyses, and significance is denoted by asterisks (n ⫽ 3; *, P ⬍ 0.05). C,
PCNA IHC analyses of P0 tibia from cartilage-specific GSK-3␤ KO mice and control littermates
(Cont). D, PCNA staining quantified as fraction of positive stained cells. Results were
compared by t test (n ⫽ 3; *, P ⬎ 0.05).

GSK-3 inhibition increases
chondrocyte proliferation
To determine why ex vivo inhibition
of GSK-3 affects bone growth whereas in
vivo GSK-3␤ deletion had no observable
effect, the cellular mechanisms controlling growth plate dynamics were explored. Because the rate at which chondrocytes cycle through the growth plate
stages determines both zone morphology
and bone growth, chondrocyte proliferation was assessed through IHC analyses
using PCNA antibodies (Fig. 5). The
PCNA IHC was quantified as the fraction of positively stained cells per total
number of cells. GSK-3 inhibition (SB86)
did increase the amount of actively proliferating cells in the tibia organ culture
almost 2-fold (Fig. 5, A and B). Proliferation was not significantly decreased below the control levels upon treatment
with the PI3K inhibitor (LY), whereas
treatment with both inhibitors increased
proliferation significantly over the LY
treatment, similar to the effect of GSK-3
inhibition only (Fig. 5B). Similar data
were obtained using bromodeoxyuridine
labeling and detection (Supplemental
Fig. 1G). In contrast, no difference in the
fraction of PCNA-positive chondrocytes
was observed upon cartilage-specific
GSK-3␤ deletion (Fig. 5, C and D).
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Up-regulation of GSK-3␣ protein
in response to GSK-3␤ deletion
in vivo
The two forms of GSK-3, ␣ and ␤,
play both overlapping and distinct roles
(16, 17, 28, 29, 31). GSK-3␣ levels and
overall phosphorylation of the GSK-3
FIG. 6. GSK-3 regulates p57 expression in the prehypertrophic zone in vitro, whereas
proteins were examined to understand
cartilage-specific GSK-3␤ deletion does not affect p57 expression in vivo. A, IHC analyses of
p57 expression in paraffin sections of tibia organ culture treated with GSK-3 inhibitor (10 M
the apparent lack of phenotype in the
SB86), PI3K inhibitor (10 M LY), a combination of both inhibitors (10 M SB86 plus 10 M
cartilage-specific GSK-3␤ KO mice
LY), or DMSO [control (Cont)]. Black boxed insets are higher-magnification images depicting
(Fig.
8). Surprisingly, Western blotting
the zones of p57 staining (black arrows). Far right image is a higher-magnification (boxed
area) of staining to determine cellular localization. B, Quantification of the length
demonstrated an approximately 2-fold
(micrometers) of the zone of p57 staining observed in A. Data were analyzed by one-way
increase in GSK-3␣ protein in KO carANOVA with a Tukey posttest with significance denoted by asterisks (n ⬎ 3; *, P ⬍ 0.01). C,
tilage (Fig. 8, A and B). IHC further supIHC analysis of p57 expression in paraffin sections of P0 tibias of cartilage-specific GSK-3␤ KO
mice compared with littermate controls (Cont).
ported these data by showing an increase in GSK-3␣ protein throughout
zone, although not statistically significantly (Fig. 6, A and the prehypertrophic and hypertrophic area as well as the
B). This p57-positive staining was localized to the cell nu- resting zone and articular surface (Fig. 8C). To a lesser
cleus in the prehypertrophic zone (Fig. 6A, far right inset). extent, an increase in GSK-3␣ protein was observed in the
In cartilage-specific GSK-3␤ KO mice, p57 protein ex- proliferating zone (Fig. 8C). There was no obvious change
pression was similar to that of control littermates (Fig. in the total phosphorylation of the GSK-3 proteins in all
6C), and quantification did not show any significant zones (Fig. 8D), providing further evidence that up-reguchange in the length of the p57-positive zone (data not lation of GSK-3␣ compensates for the loss of GSK-3␤ in
shown).
cartilage.

␤-Catenin expression in prehypertrophic
chondrocytes is up-regulated upon inhibition of
GSK-3
Arguably the most studied downstream target of GSK-3
is the transcription factor ␤-catenin, a target of the canonical
Wnt pathway that is a central regulator of skeletal development (7, 55–59). An increase in the amount of ␤-catenin
protein was observed specifically throughout the prehypertrophic/hypertrophic zone of tibias in organ culture treated

Discussion
This study contributes important and novel data to our
understanding of both skeletal development and GSK-3
signaling. Our results demonstrate profound effects of
GSK-3 inhibition on bone growth in a tibia organ culture
system, which is contrasted by minimal phenotypes observed upon cartilage-specific deletion of GSK-3␤. This
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with the GSK-3 inhibitor (Fig. 7A). IHC
for ␤-catenin was also performed on the
other two treatments discussed above,
LY and SB86 plus LY; however, PI3K inhibition yielded no change, and dual inhibition results were inconclusive (data
not shown). Western blot showed no significant change in ␤-catenin protein levels in the growth plate of cartilage-specific GSK-3␤ KO mice, although levels
consistently appeared increased in mutant cartilage (Fig. 7B). However, IHC
suggested that ␤-catenin levels are increased in specific subsets of chondrocytes in cartilage-specific GSK-3␤ KO
mice, in particular prehypertrophic
chondrocytes and the articular surface
(Fig. 7C).
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tiation, and replacement of cartilage by
bone) occur at a faster rate upon GSK-3
inhibition, thus resulting in increased
bone growth. The reduced length of the
hypertrophic zone would therefore not
be due to delayed differentiation but
rather to faster turnover of hypertrophic cartilage to bone.
Our observations of increased
chondrocyte proliferation and accelerated bone maturation in response to
GSK-3 inhibition are opposite to findings from Naski and colleagues (60)
who showed that a different pharmacological GSK-3 inhibitor reduced
chondrocyte proliferation and differentiation in a metatarsal organ culture system. These differences might
be due to the nature and/or concentration of the inhibitors, the duration
of treatment, or the identity of the
skeletal elements investigated, suggestingthattheeffectsofGSK-3incartilage
might be context dependent. However,
our data showing that GSK-3 inhibition promotes endochondral bone
growth, which is unlikely to occur
when both proliferation and hypertrophy of chondrocytes are inhibited, are
supported by a recent in vivo study
where loss of one allele of the Gsk3b
FIG. 7. GSK-3␤ regulates ␤-catenin expression in the prehypertrophic zone. A, Sections of
tibia organ cultures treated with a GSK-3 inhibitor (10 M SB86) or DMSO [control (Cont)]
gene rescues the dwarfism of mice dewere analyzed by IHC using ␤-catenin antibodies. Black brackets indicate the zone of ␤ficient for cGMP-dependent kinase II
catenin-stained cells in the prehypertrophic zone. B, Western blot analyses of P0 growth plate
(cGKII), another upstream inhibitor of
(GP) protein extracts from cartilage-specific GSK-3␤ KO mice and control (Cont) littermates
probed with ␤-catenin antibodies, with ␤-actin as loading control. C, Localization of ␤-catenin
GSK-3 (24). cGKII is a key mediator of
protein was conducted by IHC using ␤-catenin antibodies on paraffin tibia sections from mice
the anabolic effects of C-type natridescribed in B.
uretic peptide on endochondral bone
growth (61). These data by Kawasaki et
absence of phenotype is likely due to compensatory upal. (24) show that inhibition of GSK-3 activity is required
regulation of GSK-3␣ expression, a mechanism that has,
for the anabolic effects of cGKII in bone, an effect we
to our knowledge, not been reported for any other tissue
mimic by pharmacological inhibition of GSK-3.
or context.
Our data also provide insights into the relationship beOur tibia organ culture experiments show that inhibitween
PI3K and GSK-3 signaling in cartilage. PI3K inhition of GSK-3 results in increased longitudinal growth of
endochondral bones. This was likely caused, at least in bition resulted in decreased phosphorylation (indicating
part, by increased proliferation of chondrocytes in the increased activity) of GSK-3. In agreement with these data,
resting and proliferating zones. The shortened hypertro- pharmacological inhibition of GSK-3 rescued many of the
phic zone resulting from GSK-3 inhibition appears to be effects of the PI3K inhibitor, in particular on bone growth.
counterintuitive to the increase in growth observed by us. However, this was not true for the length of the hyperHowever, the larger proportion of PCNA-labeled chon- trophic zone, which was reduced by either inhibitors indrocytes, the increase in p57 staining, and the relative in- dividually or in combination. However, these effects on
crease in the length of the mineralized zone all suggest that the hypertrophic zone could be due to the different mechall processes in the growth plate (proliferation, differen- anisms, because PI3K inhibition appears to delay chon-
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GSK-3␣. These different expression patterns were also shown at the mRNA level
in our earlier microarray studies on microdissected mouse growth plates (64).
More importantly, GSK-3␣ expression
was up-regulated markedly in all zones of
the growth plates of Gsk3b-mutant mice,
even where very low levels of GSK-3␤
were seen in wild-type mice (such as in the
proliferative zone). These data suggest
that GSK-3␣ is able to compensate for
most functions of GSK-3␤ in chondrocytes. However, our results cannot exclude alternative explanations for the
lack of a phenotype in our KO mice; analyses of double-KO mice for both Gsk3
genes will be required to firmly establish
redundant functions of these two genes.
The molecular basis of the increase
in GSK-3␣ levels in our mutants is
currently unknown. Because GSK-3␤
regulates the stability of many other
proteins (65), it is tempting to speculate that loss of GSK-3␤ leads to stabilization of GSK-3␣ protein. However, to our knowledge, no such cross
talk between the two GSK-3 proteins
has been described. Alternatively, it is
plausible that increased GSK-3␣ expression in our KO mice is due to increased transcription, mRNA stabilFIG. 8. In vivo deletion of GSK-3␤ causes up-regulation of GSK-3␣ protein in chondrocytes.
ity, and/or translation. Future studies
A, Western blot analyses of GSK-3␣ protein in growth plate (GP) protein extracts of cartilagespecific GSK-3␤ KO and control (Cont) mice, with ␤-actin as loading control; B, densitometric
will need to address the mechanisms
quantification of GSK-3␣ Western blot analyses (A); statistical analysis was conducted using t
involved.
test, and significance is indicated by asterisk (*) (n ⫽ 3, *: P ⬍ 0.05); C, IHC analyses using
The one exception to compensation apGSK-3␣ antibodies on paraffin sections of P0 KO and control tibias; D, IHC analysis using
antibodies detecting the phosphorylated state of both GSK-3 forms, ␣ and ␤.
peared to be up-regulation of ␤-catenin
protein levels in specific chondrocytes of
cartilage-specific Gsk3b KO mice, suggestdrocyte hypertrophy and the associated bone growth (15)
ing that GSK-3␣ is not able to fully substitute for GSK-3␤
(reviewed in Ref. 62), whereas our data presented here
function in all chondrocytes. Because this effect was seen in
suggest that GSK-3 inhibition accelerates the replacement
only a few chondrocytes, it was not reflected in Western blot
of hypertrophic cartilage by mineralized tissue. Furthermore, the similar effects of both inhibitors on the hyper- analyses of extracts from the entire cartilage, but it was very
trophic zone reflect the fact that PI3K also acts through reproducible in immunohistochemical analyses of tissue secother downstream effectors in addition to GSK-3 (63), tions. Notably, increased staining for ␤-catenin in mutant
whereas GSK-3 is also involved in the response to signals mice was seen in exactly those cells that express detectable
levels of GSK-3␤ in wild-type mice (e.g. articular and prenot mediated by PI3K, such as Wnts.
Given the significant impact of GSK-3 inhibition in organ hypertrophic/hypertrophic chondrocytes), suggesting that
culture, the absence of a clear phenotype in cartilage-specific GSK-3␣ cannot fully compensate for this aspect of GSK-3␤
Gsk3b KO mice was surprising. However, our subsequent function in these cells. The reason for this inability is unclear
molecular analyses revealed the putative explanation. First, but might be related to the particular levels of expression of
the expression of GSK-3␤ in cartilage is quite restricted, at the two GSK-3 proteins in specific chondrocyte populations.
least in comparison with the more ubiquitously expressed Analyses of double mutants for both Gsk3 genes will provide
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at least over the time frame evaluated here. It will be interesting to examine in the future whether increased ␤-catenin
or other aspects of cartilage-specific loss of GSK-3␤ alters the
susceptibility to cartilage degeneration in osteoarthritis.
In closing, we believe that this study contributes important and novel information to our understanding of the complicated relationship between the two GSK-3 proteins as well
as to our understanding of the signaling pathways controlling endochondral bone development. Additional studies,
such as the simultaneous inactivation of both Gsk3 genes
in cartilage, will further elucidate the role of these key
signaling molecules in the physiology and pathophysiology of cartilage.
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